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ABSTRACT. Typically, colonic absorption of a drug is mandatory for a sustained release formulation to
hold the drug’s plasma level for more than 12 or 24 h above the minimum therapeutic plasma concentra-
tion (efficacy). According to Drugs@FDA, only 7.4% of the oral drugs are extended release forms
probably showing colonic absorption. Therefore an early determination of a drug’s colonic absorption
using the IntelliCap® in animals or humans will provide the mandatory information to initiate or stop a
SR form development. Diltiazem (60 mg) is used in the oral swallowable IntelliCap® and the marketed
SR form from Mylan (coated beads). A human study with 14 healthy volunteers compared the Mylan
formulation with the IntelliCap® device that releases the drug identical to the in-vitro dissolution of the
Mylan product. The plasma profiles of IntelliCap® and Mylan formulation are highly similar. The mean
AUC (bioequivalence fulfilled) and mean Cmax of IntelliCap® shows only a difference of +15% and
−12%, respectively. But the PK profile of the Mylan formulation shows a broader peak around Cmax.
About 81.8% diltiazem was absorbed in the colon (IntelliCap®) comparable to former publications. The
Mylan is a SR diffusion coated beads form whereas the IntelliCap® is a monolithic capsule. The beads are
transported in the gut and spread which results in a longer Tmax and a broader Cmax peak. The
IntelliCap® device can quantitatively measure the colonic absorption of a drug in excellent accordance
to a standard oral SR dosage form.
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INTRODUCTION
Many sustained release (SR) dosage forms are on the
market. The main motivation for a new drug to develop a
SR dosage form is a short half-live of the drug requiring
two or more applications per day. Typically, a continuous
absorption of the drug for 10–20 h is necessary to main-
tain plasma concentration of a drug to exceed the mini-
mum therapeutic level.
The normal human transit time from ingestion of the
dosage form to passing the illeo-ceacal valve is about 5 h
(1) in fasted, healthy volunteers. If a drug has no colonic
absorption and has a short half-life the transit time in the
small intestine (<5 h) is typically not long enough to hold
the drug’s plasma concentration for 12 or 24 h above the
therapeutically necessary level. Therefore colonic absorp-
tion of a drug is mandatory to guarantee the drug’s effi-
cacy and that bid or QD dosing can be applied.
According to the database Drugs@FDA (2), representing
about 24,000 US drug products, only about 7.4% of all oral
dosage forms (∼17,000) are extended release ones (1,200).
The different number of dose strengths of one drug in a drug
product can be neglected because the large number of prod-
ucts equals out this difference. Therefore one can conclude
that also only 7.4% of all new drug substances will have
properties that allow colonic drug absorption. That means
for a new drug to be developed as SR form the chance for a
successful market introduction is less than 7.4%. The FDA
database is using the term extended release for all modified
release forms such as delayed, sustained, pulsed release. Thus
the sustained release dosage form part is assumed to be much
lower. Therefore if a new drug requires a SR form an early
determination of a drug’s colonic absorption is of high benefit
but not routinely done in Pharmaceutical Industry.
A new oral swallowable device (IntelliCap®) now can be
used in animals or humans (3) (4). Using the IntelliCap®
system the information whether the drug does have sufficient
colonic absorption can be provided quickly. Based on these
facts an unambiguous decision to develop or stop the
sustained release (SR) form can be made. This is beneficial
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for the Pharmaceutical Industry because there is a high likeli-
hood that a new drug does not have colonic absorption and in
this case the technical as well as clinical or pre-clinical devel-
opment cost and time are lost. In addition, the capacity spent
for such unsuccessful project cannot be used for a more prom-
ising one.
This paper is describing the first human study and its
results using a drug (diltiazem) in the IntelliCap® to show
how the regional absorption of a drug can be measured,
quantified, and related to literature data.
MATERIALS AND METHODS
IntelliCap® Device
The IntelliCap® device is an oral, single use, swal-
lowable electronic device. It has the size of 000 hard-
gelatin capsule (approximately 27×11 mm). It consists of
a body and a cap. The cap is clipped onto the body. The
cap consists of the medication container that can be filled
with 0.3 ml of a drug liquid formulation (e.g., solution or
suspension). The body contains a micro-computer and
wireless data exchange unit, a temperature and pH sensor
(accuracy ±0.1 pH units), a stepper motor with spindle
and piston (see Figs. 1 and 2). The IntelliCap®’s μ-com-
puter is programmed before ingestion to control the step-
per motor and the release profile and location. By
combining control of the stepper motor with variable time
intervals allows to realize any drug release profile over
time. In addition, the IntelliCap® can be also controlled
manually in real-time from a laptop. For instance if a 6-h
zero-order (linear) release profile has been programmed
into the IntelliCap® the start of this profile can be
commanded from the laptop when the IntelliCap®
reached a particular location along the GI tract(e.g., the
pylorus). Real-time localization of the IntelliCap® within
the gut is achieved by monitoring individual pH profile
(5). The set-up of the IntelliCap® before ingestion is
described in Fig. 3.
Test Article, Dose and Formulations
Diltiazem HCl (CID: 62920) extended release cap-
sules 60 mg (Mylan Pharmaceuticals Inc., Morgantown,
WV 26505, USA containing 55.1 mg diltiazem free base)
was sourced by ProMedica Clinical Research Center
(Brighton, MA). In this article, it is denoted Mylan
ER® (extended release). Diltiazem-HCl powder was
sourced as well by ProMedica Clinical Research Center
(Brighton, MA). Diltiazem has a molecular weight of
414.5 (free form), a pKa of 8.06 (weak base), a water
solubility of 465 mg/mL (6) and a log P of 2.79.
Diltiazem is a BCS class 1 drug (7), bioavailability is
about 40–50%, the drug is a substrate of CYP3A4 (N-
demethylation, about 80%), of CYP2D6 (O-demethyla-
tion, about 10%), of esterases (desacetylation, about
10%) (8) and substrate of P-glycoprotein (9).
The IntelliCap® is filled with approximately 300 μL of an
aqueous solution of diltiazem HCl (270 mg/mL). The
IntelliCap® capsule is programmed to release approximately
220 μL of this solution over a time period of 24 h with a first-
order release profile mimicking the release profile of the
marketed 60-mg extended release capsule according to USP
Drug Release Test 2 (Fig. 4).
The actual dose released during the gut transit from the
IntelliCap® was determined by analyzing the remaining dilti-
azem content in the excreted IntelliCap®. The drug content
was determined using a UV method. This drug amount was
Fig. 1. The IntelliCap® device and its parts
Fig. 2. IntelliCap® wireless data exchange scheme
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subtracted from the amount that was filled in the medication
container. This procedure was done for all subjects except one
that could not recover the IntelliCap® after excretion. In this
subject, an abdominal X-ray confirmed (6 days after adminis-
tration) that the capsule was not withhold. This results in a
mean released dose of 64.8 mg.
Clinical Study
The study used an open-label, randomized, two-peri-
od crossover design with a minimum washout period of
1 week. The study was approved by an Institutional
Review Board (New England IRB, Newton, MA, USA)
and was conducted at Promedica Clinical Research Center
(Brighton, MA, USA). The human study is registered as
ISRCTN45336965 (10).
Health Volunteers
In total, 14 healthy, male, non-smoking volunteers
were enrolled. To participate, subjects had to be between
18 and 45 years of age with a BMI between 18 to 29 kg/
m2 and a min imum weight of 50 kg . Pr ior to
administration, subject’s health status was examined
including medical history, physical examination, vital
s i gns , e l ec t rocard iogram, and labora to ry te s t s
(hematology, blood chemistry, urinalysis, hepatitis B and
C, HIV). Subjects with swallowing disorders, implanted
medical devices, gastrointestinal diseases (inflammatory
bowel disease, ulcers, gastrointestinal or rectal bleeding),
major gastrointestinal surgery were excluded from
participation. Subjects taking prescription drug prior
1 month or over the counter medication within 2 weeks
before administration were not enrolled into the study.
Written informed consent was obtained from all
participating volunteers.
Dosing
After an overnight fast, subjects were administered at
around 8 AM either one IntelliCap® capsule with diltiazem
HCl aqueous solution (∼0.3 ml of 270 mg/mL) or one diltia-
zem extended release capsule (60 mg) with 240 mL of water.
The IntelliCap® capsule was programmed to release its pay-
load over time resembling the in vitro dissolution profile of the
60-mg Mylan ER capsule (Fig. 4) starting immediately after
administration. Subjects remained fasted for 5 h after admin-
istration. After 5 h, subjects returned to a regular meal
schedule.
Sampling
Blood samples (6 mL) were collected at pre-dose, 1,
2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 24, 36, and 48 h post-
Fig. 3. The set-up procedure for the IntelliCap®
Fig. 4. In vitro dissolution profile of Mylan ER® (60-mg capsule) and
IntelliCap® releasing diltiazem solution (900 mL H2O, 37°C, 100 rpm, pad-
dle). Diltiazem HCl was quantified spectro-photometrically at 239 nm
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administration. Diltiazem was quantified in plasma using a
validated liquid chromatography tandem mass spectrome-
try method with a lower limit of quantification of 0.2 ng/
mL in 200 μL plasma. Human heparinized plasma samples
(200 μl), 20 μl of D4-diltiazem internal standard and
800 μl acetonitrile are mixed and centrifuged. A portion
of the supernant is injected in UPLC ESI+MS/MS.
Quantitation of diltiazem is performed by using an analyte
to internal standard ratio and a concentration-weighted
linear regression.
Determination of Gastrointestinal Transit Times
Individual gastrointestinal transit times (gastric resi-
dence, small bowel transit, colon transit, and whole gut
t rans i t ) were determined f rom subjec t s in the
IntelliCap® arms using the pH and temperature/time
data. The gastrointestinal pH and temperature profiles
recorded by the IntelliCap® capsule were analyzed for
capsule ingestion resulting in a rapid and sustained rise
in temperature from room to body temperature. The
pylorus passage is characterized by a rapid and sustained
rise from the acidic stomach environment into the neu-
tral pH of the duodenum (approximately pH 6). The
ileo-cecal valve passage is observed when drop of >0.5
pH units occurs that is caused by the acidic bacterial
digestion products in the colon. Finally, anal excretion
causes a rapid and sustained drop in temperature from
body to room temperature (see Fig. 5).
Pharmacokinetics
The following plasma pharmacokinetic parameters have
been determined for diltiazem:
AUClast;AUC0−t;AUC∞;Cmax;Tmax;T lag;T1=2;Vd=F;CL=F:
Pharmacokinetic parameters were determined using non-
compartmental method(s) using WinNonlin Pro 6.2
(Pharsight, USA).
Calculation of Regional Absorption
Gastro plus® version 8 (Simulations plus Inc.;
Lancaster; USA) has been used to calculate regional ab-
sorption of this study (mean Cp versus time) by using a
model having a goodness of fit R=0.72. The iv data used
in this model are taken from (11). The important param-
eters for the model for Diltiazem in the IntelliCap® are
summarized in Table I
The same model was used for the Mylan ER for-
mulation as dose form “CR Dispersed” in Gastro Plus
and had a goodness of fit of 0.75. The transit times of
this formulation are not measured and therefore the
IntelliCap® transit times were used. The observed
plasma concentrations of diltiazem versus the simulat-
ed concentrations are shown in Figs. 6 and 7.
RESULTS
All subjects enrolled in the study completed the study.
The IntelliCap® system was safe and well-tolerated in healthy
volunteers. No adverse events or adverse device effects were
observed.
Fig. 5. Localization of gut regions by pH and temperature data
Table I. Important Parameters used in Gastro Plus to Model the Cp/
Time Curve
Parameter Value
Dose form CR integral tablet
Solubility 465 mg/mL (pH 7.2)
logP neutral 2.79
Liver first pass 70%
Clearance 39.4 L/h
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PK data from all subjects were included in the statistical
analysis. Summary plasma time profiles and statistics for the
PK parameters are provided in Fig. 8 and Table II, respective-
ly, and are also shown in (12).
The mean cecum arrival time for the IntelliCap® is 5:34
hh:min (Table III). The Tmax for the IntelliCap® is 6:18
hh:min (Table II). There is a data caption rate of less than
1 min for the pH that determines the cecum arrival time
compared to an hourly blood sampling. Considering these
facts the Tmax and cecum arrival can be regarded nearly
identical.
DISCUSSION
The mean PK data of both formulations are very similar.
Considering the Mylan ER formulation as reference the
IntelliCap® deviates only slightly from the reference and
within the error range especially for AUC +15% and Cmax
−12%. But despite the fact that the dissolution profiles of both
dosage forms superimpose, the PK profiles show differences:
– longer Tmax for Mylan ER
– higher Cmax for Mylan ER
– longer Tlag for Mylan ER
– less of the dose is absorbed by Mylan ER
Fig. 6. IntelliCap® mean drug plasma concentration versus time with standard deviation as
error bars (squares: observed, solid line: simulated results from Gastro plus)
Fig. 7. Mylan ER mean drug plasma concentration versus time with standard deviation as
error bars (squares: observed, solid line: simulated results from Gastro plus)
1494 Becker et al.
The longer Tmax and higher Cmax of the Mylan
formulation can be explained. The used dosage forms
are different. The IntelliCap® is a monolithic unit and
the Mylan ER are diffusion coated beads in a capsule.
For multi-particulate systems it is well-known that they
accumulate and stagnate in front of ileo-cecal valve (13–
15). In addition the transit time in the small intestine is
nearly invariable for monolithic or multiparticulate dosage
forms (16) and also no difference can be seen in gastric
emptying (17–19) for both forms. Therefore the
IntelliCap® will arrive at the ileo-cecal valve approxi-
mately at the same time as the first pellets. The pellets
tend to spread in the small intestine and will be
transported when they arrive into the colon (20). This
resu l t s in a la ter Tmax by about 2 h for the
multiparticulate form and therefore they stay longer in
the small intestine at least in part and increase Cmax.
Consequently, at this time when the pellets are partly in
the ileum and in the colon, the diltiazem plasma concen-
tration profile is less steep after 6 h compared to the
graph between 4 and 6 h.
The longer lag time seen in the mean plasma profiles is
misleading probably because of the high variability. The cal-
culated Tlag times are very similar (Table II).
The lower drug exposure produced by the Mylan ER
is probably due to the water dependent passive diffusion
release mechanism of the pellets. The IntelliCap® is
using an active pump system that is releasing drug inde-
pendently from the environmental water concentration
especially in the colon. Therefore, due to the fact that
water reduction in the colon is drastic (21) and water is
the driving force for the drug release from the pellets.
This is evident from Figs. 9 and 10 when comparing the
in vivo dissolution and fraction absorbed showing a low-
er total Fa for the Mylan ER and a much stronger
decline in Fa in the colon (between 12 and 24 h) com-
pared to the IntelliCap®. This is also confirmed in an
article by Lennernäs (7). There are two drugs among 42
drugs that have been used in two different formulations
in the colon. AZ6 was intubated as solution and granules
and dexloxiglumide was released from an Enterion cap-
sule as solution and powder. In both cases the solution
was better absorbed by the colon. This is in line with the
observation that the active pump system of the
IntelliCap in colon added about 0.2 ml to the overall
colonic fluid volume of 10–20 ml (21). The Lennernäs
(7) paper also stated that drugs showing high permeabil-
ity do have better colonic absorption of about 70% rel-
ative to the absorption in the small intestine (100%) in
comparison with low permeable drugs. But this analysis
is based on drugs that all have colonic absorption which
is a rare drug property.
Another indication of colonic absorption can be ob-
served in the mean diltiazem plasma profiles. Typically for
a drug that does not show any colonic absorption, the
plasma profile will decline after reaching Cmax in a more
or less exponential way comparable in shape to an iv
injection as can be seen on Fig. 8 for diltiazem iv. If a
drug like diltiazem has significant colonic absorption, the
shape of the plasma profile after Cmax becomes different
by the additional drug input as can be seen on Fig. 8
especially for the IntelliCap® profile between 6 and
12 h. According to Wilson (22), the transit time in the
Fig. 8. Plasma concentration versus time profile of the Mylan ER
(diamonds) and IntelliCap® (squares) formulation in healthy volun-
teers (N=14) and the iv bolus solution 20 mg (circles) from Reference
(11). The cecum transit time of the IntelliCap is marked
Table II. Important PK Results % CV in Parenthesis (All Absorption
Data Calculated with Gastro Plus)
PK parameter Mean Mean
Dosage form IntelliCap® Mylan ER
Dose (mg; diltiazem HCl) 64.8 60.0
Cmax (ng/ml) 34.7 (28.8) 39.5 (33.9)
AUClast (ng×h/ml) 494.0 (63.4) 428.0 (39.1)
Tmax (h) 6.3 (37.1) 8.0 (24.0)
Tlag (h) 0.5 0.7
T½ (h) 6.6 (22.3) 6.1 (20.0)
Volume of distribution/F (L) 1,600 (59.5) 1,420 (47.8)
Total clearance/F (L/h) 177 (65.1) 163 (47.1)
Absorption small intestine (%) 10.6 12.7
Absorption colon (%) 81.8 65.6
Total absorption (%) 92.4 78.3
Literature colonic absorption (%) (7) 82
Table III. Mean Gastrointestinal Transit Times in IntelliCap® Arm
(hh:mm)
GRT SBTT CTT WGTT
Mean 01:09 04:25 34:17 39:51
SD 01:04 01:03 27:00 27:21
Min 00:12 02:18 05:30 08:06
Max 03:44 06:19 98:47 104:05
GRT gastric residence time, SBTT small bowl transit time, CTT colon
transit time, WGTT whole gut transit time
CTT and WGTT: in two subjects portable unit run out of battery
power, determined from subject reported time of excretion
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ascending colon is about 3 to 5 h and in the transverse
colon 0.2 to 4 h. The colon entry time of the IntelliCap®
is about 5.5 h and can be projected to be around 8.2 to
14.5 h entering the descending colon. This is in good
accordance to the drug input seen in the colon between
6 and 12 h.
In addition, the plasma profile is showing a reduced input
rate of diltiazem from the IntelliCap® between 6 and 12 h.
This is also reported by Lennernäs (7) for diltiazem which had
an increased Tmax and decreased Cmax when directly
instilled into the colon compared to the absorption in the small
intestine.
Interestingly, these differences observed of a drug
released by an active pump versus passive diffusion in
the pellets can be simulated using PBPK software as
shown above. The device in combination with PBPK soft-
ware can therefore contribute significantly in the elucida-
tion of the quantitative relation of a drug’s local gut
solubility, precipitation, metabolism in gut wall and the
liver, and the impact of transporters resulting in the
finally measured systemic drug plasma concentration pro-
file. Especially because solubility, metabolism, and trans-
porter impact can be measured in vitro and entered into
PBPK models that predicts well the measured data. This
will allow to simulate the currently often unknown part of
precipitation of a drug in the gut by using the accurately
known dose pumped out by the device. But this important
aspect needs further investigations also because the regu-
latory agencies meanwhile show interest in PBPK simula-
tion and work on guidelines (23).
CONCLUSION
IntelliCap® determines and quantifies colonic absorption
of a drug (using simulation software, e.g., Gastro plus) in
excellent accordance to published data.
The study proves that the IntelliCap® is a very
beneficial tool to assess the extent of colonic absorption
for drug and thereby providing the mandatory informa-
tion to make a scientifically sound early GO / NOGO
Fig. 9. IntelliCap® results from Gastro plus: In vivo dissolution (red solid line), fraction
absorbed Fa (blue line), and total systemic concentration (green line)
Fig. 10. Mylan ER results from Gastro plus: In vivo dissolution (red solid line), fraction
absorbed Fa (blue line) and total systemic concentration (green line)
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decision on development of a modified release dosage
form. This i s of paramount importance for the
Pharmaceutical Industry because a significant propor-
tion of new drugs (>90%) do not have sufficient colonic
absorption that would allow a sustained release formu-
lation to be developed.
Open Access This article is distributed under the terms of
the Creative Commons Attribution License which permits any
use, distribution, and reproduction in any medium, provided
the original author(s) and the source are credited.
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